Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genentech rejects Roche offer

Genentech (NYSE:DNA) said a special committee of the company's board rejected an offer by Roche (SIX:ROG) to acquire the

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE